dm+d

Unassigned

New Medicines

Malignant pleural mesothelioma - first-line with pemetrexed and cisplatin

Information

New molecular entity
Polaris
Polaris

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

ADI-PEG 20 works by systemically depleting the external supply of arginine and causes these arginine-dependent cancer cells to die while leaving the normal cells unharmed
Mesothelioma is almost always caused by exposure to asbestos. The worldwide incidence of the disease continues to increase; in Western Europe, more than 5,000 new cases per year are estimated to occur, with more than a quarter of a million deaths expected to occur over the next 40 years. The number of patients diagnosed in 2014 with malignant pleural mesotheliomas (MPM) in England was 2,179 with a median age of 75 years. MPM predominantly affects men – 83.4% of patients were male [1].
Malignant pleural mesothelioma - first-line with pemetrexed and cisplatin
Intramuscular

Evidence based evaluations